ASCO: BioNTech's Roche-partnered cancer vaccine combo hints at survival benefit in prostate cancer

A year and a half after debuting on the world stage with its Pfizer-partnered COVID vaccine, BioNTech wants to prove it’s not a one-hit wonder, touting early data of a pancreatic cancer vaccine combo that suggest a delay in tumor recurrence.